Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults

References

• Gupta AK, Nakrieko K-A. Molecular determination of mixed infections of dermatophytes and nondermatophyte moulds in individuals with onychomycosis. J Am Podiatr Med Assoc 2013; In press
   Web of Science ®Google Scholar
• Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses 2008;51(s4):2-15
   PubMedGoogle Scholar
• De Berker D. Fungal nail disease. N Engl J Med 2009;360(20):2108-16
   PubMed Web of Science ®Google Scholar
• Shemer A. Update: medical treatment of onychomycosis. Dermatol Ther 2012;25(6):582-93
   PubMed Web of Science ®Google Scholar
• Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol 2011;65(6):1219-27
   PubMed Web of Science ®Google Scholar
• Elewski BE. Onychomycosis: treatment, quality of life, and economic issues. Am J Clin Dermatol 2000;1(1):19-26
   PubMedGoogle Scholar
• Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002;138(3):353-7
   PubMedGoogle Scholar
• Shuster S, Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Derm Venereol 2001;81(1):154-5
   PubMedGoogle Scholar
• Haneke E. Fungal infections of the nail. Sem Dermatol 1991;10(1):41-53
   PubMedGoogle Scholar
• Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population – A literature study. J Eur Acad Dermatol Venereol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004;50(5):748-52
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Hajjeh RA, Scher RK, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43(4):641-8
   PubMed Web of Science ®Google Scholar
• Scher RK, Rich P, Pariser D, Elewski B. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg 2013;32(2 s1):S2-4
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Srivastava G, Dogra S, et al. Onychomycosis: an Asian perspective. Skinmed 2010;8(1):37-45
   PubMedGoogle Scholar
• Tan HH. Superficial fungal infections seen at the National Skin Center. Singapore. Nihon Ishinkin Gakkai Zasshi 2005;46:77-80
   PubMedGoogle Scholar
• Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians’ offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43(2):244-8
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Kristinsson KG, Jónasson PS. Onychomycosis in icelandic children. J Eur Acad Dermatol Venereol 2006;20(7):796-9
   PubMed Web of Science ®Google Scholar
• Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007;20(1):31-46
   PubMed Web of Science ®Google Scholar
• Scherer WP, McCreary JP, Hayes WW. The diagnosis of onychomycosis in a geriatric population: a study of 450 cases in South Florida. J Am Podiatr Med Assoc 2001;91(9):456-64
   PubMed Web of Science ®Google Scholar
• Effendy I, Lecha M, Feuilhade de Chauvin M, European Onychomycosis Observatory. Epidemiology and clinical classification of onychomycosis. J Eur Acad Dermatol Venereol 2005;19(s1):8-12
   PubMedGoogle Scholar
• Ogasawara Y, Hiruma M, Muto M, Ogawa H. Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. Mycoses 2003;46(3–4):114-19
   PubMed Web of Science ®Google Scholar
• Djeridane A, Djeridane Y, Ammar-Khodja A. Epidemiological and aetiological study on tinea pedis and onychomycosis in Algeria. Mycoses 2006;49(3):190-6
   PubMed Web of Science ®Google Scholar
• Thomas J, Jacobson GA, Narkowitz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 2010;35(1):497-519
   PubMedGoogle Scholar
• Tosti A, Hay R, Arenas-Guzman R. Patients at risk of onychomycosis – risk factor identification and active prevention. J Eur Acad Dermatol Venereol 2005;19(Suppl 1):13-16
   PubMed Web of Science ®Google Scholar
• Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997;36(10):754-6
   PubMed Web of Science ®Google Scholar
• Fouilloux B. Onychomycosis and quality of life. Ann Dermatol Venereol 2003;130(12 Pt 2):1275-8
   PubMed Web of Science ®Google Scholar
• Daniel RC. Onychomycosis: burden of disease and the role of topical antifungal treatment. J Drugs Dermatol 2013;12(11):1263-6
   PubMed Web of Science ®Google Scholar
• Roberts DT, Taylor WD, Boyle J; British Association of Dermatologists. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148(3):402-10
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol 2013;31(5):544-54
   PubMed Web of Science ®Google Scholar
• Lecha M, Effendy I, Feuilhade de Chauvin M, et al. Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol 2005;19(s1):25-33
   PubMed Web of Science ®Google Scholar
• Thomas J, Jacobson GA, Narkowicz CK, et al. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 2010;35(5):497-519
   PubMed Web of Science ®Google Scholar
• Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses 2007;50(4):321-7
   PubMed Web of Science ®Google Scholar
• Chang C-H, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis. Am J Med 2007;120(9):791-8
   PubMed Web of Science ®Google Scholar
• Patel T, Dhillon S. Efinaconaole: first global approval. Drugs 2013;73(17):1977-83
   PubMed Web of Science ®Google Scholar
• Murdan S. Review drug delivery to the nail following topical application. Int J Pharm 2002;236(1-2):1-26
   PubMed Web of Science ®Google Scholar
• Galderma Ltd Product monograph Curanail (5% amorolfine hydrochloride) nail lacquer. Available from: www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023787.pdf [Last accessed 3 January 2014]
   Google Scholar
• Dermik Laboratories Product monograph Penlac (ciclopirox topical solution, 8% w/w) nail lacquer. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf [Last accessed 3 January 2014]
   Google Scholar
• Reinel D. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use. Dermatol 1992;184(s1):21-4
   PubMedGoogle Scholar
• Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43(4):s70-80
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;68(4):600-8
   PubMed Web of Science ®Google Scholar
• Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution – an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985;10(2):111-15
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis. Available from: http://clinicaltrials.gov/ct2/show/NCT00443820?term=terbinafine+nail+solution&rank=1 [Last accessed 3 January 2014]
   Google Scholar
• Novartis Pharmaceuticals. A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis (NCT00443898). Clinicaltrials.gov, (2007). Available from: http://clinicaltrials.gov/ct2/show/NCT00443898?term=terbinafine+nail+solution&rank=2 [Last accessed 3 January 2014]
   Google Scholar
• Ghannoum M, Isham N, Herbert J, et al. Activity of TDT 067 (terbinafine in transfersome(R)) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J Clin Microbiol 2011;49(5):1716-20
   PubMed Web of Science ®Google Scholar
• Celtic Pharma Development Services. TDT 067 onychomycosis study. clinicaltrials.gov, (2012). Available from: http://clinicaltrials.gov/ct2/show/NCT01145807 [Last Accessed 3 January 2014]
   Google Scholar
• Topica Pharmaceuticals. Safety and efficacy of luliconazole solution, 10% in subjects with mild to moderate onychomycosis. clinicaltrials.gov, (2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01431820 [Last accessed 3 January 2014]
   Google Scholar
• Alley MRK, Baker SJ, Beutner KR, Platner J. Recent progress on the topical therapy of onychomycosis. Expert Opin Investig Drugs 2007;16(2):157-67
   PubMed Web of Science ®Google Scholar
• Baker SJ, Zhang YK, Akama T, et al. Discovery of a new boron containing anti-fungal agent, 5-fluoro-1,3-dihydro- 1-hydroxy-,1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem 2006;49(15):4447-50
   PubMed Web of Science ®Google Scholar
• Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993;28(5 Pt 1):s28-34
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE, Baran R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003;21(3):481-9
   PubMed Web of Science ®Google Scholar
• Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrob Agents Chemother 2013;57(5):2405-9
   PubMed Web of Science ®Google Scholar
• Rock FL, Mao W, Yaremchuk A, et al. An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site. Science 2007;316(5832):1759
   PubMed Web of Science ®Google Scholar
• Beutner KR, Sanders V, Hold K, et al. An open-label, multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis. Anacor.com, (2007) Available from: http://anacor.com/pdf/poster_1823.pdf [Last accessed 14 January 2014]
   Google Scholar
• Mao W, Rock F, Alley MRK. AN2690, a topical antifungal agent in development for the treatment of onychomycosis represents a new class and has a novel mechanism of action. Anacor.com, (2006) Available from: www.anacor.com/pdf/SID_P769.pdf [Last accessed 14 January 2014]
   Google Scholar
• Hold KM, Bu W, Sanders V, et al. In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis. Anacor.com, (2007) Available from: http://anacor.com/pdf/poster_1816.pdf [Last accessed 14 January 2014]
   Google Scholar
• Hui X, Baker SJ, Wester RC, et al. In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96(10):2622-31
   PubMed Web of Science ®Google Scholar
• Sanders V, Baker SJ, Alley MRK, et al. Microbiological activity of AN2690, a new antifungal agent in development for the topical treatment of onychomycosis. Anacor.com, (2006) Available from: http://anacor.com/pdf/AAD_P1608.pdf [Last accessed 14 January 2014]
   Google Scholar
• Barak O, Loo DS. AN-2690, a novel antifungal for the topical treatment of onychomycosis. Curr Opin Investig Drugs 2007;8:662-8
   PubMed Web of Science ®Google Scholar
• Beutner KR, Sanders V, Hold K, et al. An open-label, multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis. Anacor.com, (2007) Available from: http://anacor.com/pdf/poster_1823.pdf [Last accessed 17 January 2014]
   Google Scholar
• Beutner K, Toledo-Bahena M, Barbosa-Alanis H, et al. Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solutions for the treatment of onychomycosis of the great toenail. Anacor.com, (2006) Available from: www.anacor.com/pdf/ESDR_P565.pdf [Last accessed 17 January 2014]
   Google Scholar
• Zane L, Pollak R. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Anacor.com, (2012) Available from: www.anacor.com/pdf/APMA%20Tavaborole%20Phase%202%20Poster.pdf [Last accessed 17 January 2014]
   Google Scholar
• Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the treatment of onychomycosis: results from two phase 3 studies. Anacor.com, (2013) Available from: http://anacor.com/pdf/Tavaborole_Phase%203%20Poster_Final%20Copy_093013.pdf [Last accessed 17 January 2014]
   Google Scholar
• Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician 2001;63(4):663-73
   PubMed Web of Science ®Google Scholar
• Chanda S, Liu L, Heyman I. Preclinical safety studies with AN2690, a novel boron-containing small molecule for topical treatment of onychomycosis, demonstrate promising safety profile. Anacor.com, (2011) Available from: http://anacor.com/pdf/ESDR_AN2690_223.pdf [Last accessed 3 January 2014]
   Google Scholar
• Anacor Pharmaceuticals Inc. Anacor Pharmaceuticals announces FDA acceptance of tavaborole NDA for filling. Anacor.com, (2013). Available from: http://investor.anacor.com/releasedetail.cfm?ReleaseID=794323 [Last accessed 17 January 2014]
   Google Scholar
• Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improve efficay of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009;23(7):773-8
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M. Improved efficacy in onychomycosis therapy. Clin Dermatol 2013;31(5):555-63
   PubMed Web of Science ®Google Scholar
• Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003;149(65):5-9
   PubMedGoogle Scholar
• Lecha M, Alsina M, Torres Rodriguez JM, et al. An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 2002;63(6):366-79
   Web of Science ®Google Scholar
• Goodfield MJD, Evans EGV. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatol Treat 2000;11(4):259-62
   Web of Science ®Google Scholar